Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5495073 | 1.00 | CA1 (0.33) | CA1CA2CA9GRIN2DGRIN3B | |
| SCHEMBL27494904 | 0.84 | MAPT (0.40) | CA1CA2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL27494903 | 0.84 | MAPT (0.40) | CA1CA2GRIN2DGRIN3BGRIN1 | |
| SCHEMBL5493590 | 0.83 | SLC7A5 (0.39) | CA1CA2CA9 | |
| SCHEMBL5493588 | 0.83 | SLC7A5 (0.39) | CA1CA2CA9 | |
| SCHEMBL19105215 | 0.81 | PKM (0.32) | CA1CA2CA9PKMSMN1; SMN2 | |
| SCHEMBL11915792 | 0.81 | ELANE (0.42) | CA1CA2CA9PKMSMN1; SMN2 | |
| SCHEMBL935390 | 0.78 | KMT2A (0.43) | — | |
| SCHEMBL17278283 | 0.78 | SLC7A5 (0.45) | MTORRAB9A | |
| SCHEMBL12831909 | 0.77 | PKM (0.31) | PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110709523-B | Sequencing reaction method using tagged nucleosides obtained via PICTET SPENGLER reaction | 豪夫迈·罗氏有限公司 | 2023-07-11 | — | — | CN | disclosed |
| US-11293060-B2 | Method for labeling of aldehyde containing target molecules | Roche Sequencing Solutions, Inc. (US) | 2022-04-05 | — | — | US | disclosed |
| EP-3609897-A1 | A METHOD FOR LABELING OF ALDEHYDE CONTAINING TARGET MOLECULES | H. Hoffnabb-La Roche Ag (CH) | 2020-02-19 | — | — | EP | disclosed |
| EP-3610040-A1 | A METHOD FOR SEQUENCING REACTION WITH TAGGED NUCLEOSIDE OBTAINED VIA PICTET SPENGLER REACTION | H. Hoffnabb-La Roche Ag (CH) | 2020-02-19 | — | — | EP | disclosed |
| CN-109564213-A | Detecting microbial wound infection | 西诺福有限公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2018191389-A1 | A METHOD FOR SEQUENCING REACTION WITH TAGGED NUCLEOSIDE OBTAINED VIA PICTET SPENGLER REACTION | Roche Sequencing Solutions, Inc. (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018189214-A1 | A METHOD FOR LABELING OF ALDEHYDE CONTAINING TARGET MOLECULES | F. HOFFMANN-LA ROCHE AG (CH) | 2018-10-18 | — | — | WO | disclosed |
| EP-1858538-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | Biomarck Pharmaceuticals, Ltd. (US) | 2007-11-28 | — | — | EP | disclosed |
| WO-2006078899-A2 | MUCIN HYPERSECRETION INHIBITORS BASED ON THE STRUCTURE OF MANS AND METHODS OF USE | BIOMARCK PHARMACEUTICALS, LTD. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11293060-B2 | Method for labeling of aldehyde containing target molecules | NUDT1, RNGTT, DERA | CA1 2925/4885CA2 2590/4885CA9 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.